Multiple System Atrophy
155
36
48
68
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
19 trials with published results (12%)
Research Maturity
68 completed trials (44% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.7%
12 terminated out of 155 trials
85.0%
-1.6% vs benchmark
6%
9 trials in Phase 3/4
28%
19 of 68 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 68 completed trials
Clinical Trials (155)
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
Clinical Laboratory Evaluation of Chronic Autonomic Failure
A Study of TAK-341 in Treatment of Multiple System Atrophy
Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France
Neurodegenerative Diseases Registry
VisMemoPD Protocol: an Observational Pilot Study on Spatial and Topographical Memory in Patients With Parkinson's Disease and Parkinsonism
Analysis of the Enteric Nervous System Using Colonic Biopsies
Expansion Study of ALT001 in Patients With Multiple System Atrophy
Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
High-Altitude Neurodegeneration Cohort (HANC) Study
Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy
Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)